Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients.
The use of magnesium in the treatment of acute myocardial infarction remains controversial despite preliminary experimental evidence that magnesium plays a beneficial role as a regulator of thrombosis. The aim of our study was to determine whether oral magnesium treatment inhibits platelet-dependent thrombosis (PDT) in stable patients with coronary artery disease (CAD). In a randomized prospective, double-blind, cross-over and placebo controlled study, 42 patients with stable CAD (37 men, 5 women, mean age 68 +/- 9 years) on aspirin received either magnesium oxide tablets (800-1,200 mg/day) or placebo for 3 months (Phase 1) followed by a 4-week washout period, and the cross-over treatment for 3 months (Phase 2). PDT, platelet aggregation, platelet P-selectin flow-cytometry, monocyte tissue factor procoagulant activity (TF-PCA) and adhesion molecules density were assessed before and after each phase. PDT was evaluated by an ex-vivo perfusion model using the Badimon chamber. Median PDT was significantly reduced by 35 percent in patients who received magnesium versus placebo (D change from baseline: -24 vs. 26 microm2/mm; p = 0.02, respectively). There was no significant effect of magnesium treatment on platelet aggregation, P-selectin expression, monocyte TF-PCA or adhesion molecules. Oral magnesium treatment inhibits PDT in patients with stable CAD. This effect appears to be independent of platelet aggregation or P-selectin expression, and is evident despite aspirin therapy. These findings suggest a potential mechanism whereby magnesium may beneficially alter outcomes in patients with CAD.
Shechter
M
M
Cedars-Sinai Burns and Allen Research Institute, Department of Medicine, Cedars-Sinai Medical Center and the UCLA School of Medicine Los Angeles, California, USA. shectes@netvision.net.il
Merz
C N
CN
Paul-Labrador
M
M
Meisel
S R
SR
Rude
R K
RK
Molloy
M D
MD
Dwyer
J H
JH
Shah
P K
PK
Kaul
S
S
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use*; D002448:Cell Adhesion; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D003327:Coronary Disease / Q000188:drug therapy*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004573:Electrolytes / Q000097:blood; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005434:Flow Cytometry; D006801:Humans; D008055:Lipids / Q000097:blood; D008274:Magnesium / Q000008:administration & dosage* / Q000627:therapeutic use*; D008277:Magnesium Oxide / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism; D019007:P-Selectin / Q000097:blood; D010919:Placebos; D010974:Platelet Aggregation / Q000187:drug effects; D011446:Prospective Studies; D013925:Thromboplastin / Q000378:metabolism; D013927:Thrombosis / Q000188:drug therapy
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D004573:Electrolytes; D005343:Fibrinolytic Agents; D008055:Lipids; D019007:P-Selectin; D010919:Placebos; D008277:Magnesium Oxide; D013925:Thromboplastin; D008274:Magnesium; D001241:Aspirin